These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 24056377)
1. [Palivizumab for respiratory syncytial virus disease]. Carrera G; D'alterio R; Leone G; Zambetti C Minerva Pediatr; 2013 Oct; 65(5):505-12. PubMed ID: 24056377 [TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related]
3. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants. Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332 [TBL] [Abstract][Full Text] [Related]
4. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776 [TBL] [Abstract][Full Text] [Related]
5. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
6. Apnea with RSV infection in three infants receiving palivizumab. Del Vecchio MT Pediatr Int; 2013 Dec; 55(6):e159-61. PubMed ID: 24330303 [TBL] [Abstract][Full Text] [Related]
7. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710 [TBL] [Abstract][Full Text] [Related]
8. Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department. Shachor-Meyouhas Y; Zaidman I; Kra-Oz Z; Arad-Cohen N; Kassis I J Pediatr Hematol Oncol; 2013 Mar; 35(2):124-8. PubMed ID: 23128340 [TBL] [Abstract][Full Text] [Related]
9. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704 [TBL] [Abstract][Full Text] [Related]
15. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit. Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712 [TBL] [Abstract][Full Text] [Related]
16. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age. Park HW; Lee BS; Kim AR; Yoon HS; Kim BI; Song ES; Kim WT; Lim J; Kim S; Jin HS; Byun S; Chee DH; Kim KS Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234 [TBL] [Abstract][Full Text] [Related]
17. [Use of palivizumab in the prevention of syncytial virus respiratory infection]. Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187 [TBL] [Abstract][Full Text] [Related]
19. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group. Carbonell-Estrany X Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453 [TBL] [Abstract][Full Text] [Related]
20. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]